Confo Therapeutics

About Confo Therapeutics

Confo Therapeutics is a clinical-stage company dedicated to identifying and accelerating novel medicines for metabolic and endocrine diseases. They utilize proprietary technology to develop small molecule and antibody-based therapies targeting GPCRs (G Protein-Coupled Receptors).

Products & Services

CFTX-1554:A non-opioid treatment for neuropathic pain targeting the angiotensin II type 2 receptor (AT2R), currently in Phase 1.

Obesity Program (GPR75):Antagonist approach targeting GPR75 for obesity treatment, in Lead Optimization stage.

Obesity Program (GLP1R, GIPR, Amylin R, GCGR):Agonist/Antagonist approach targeting multiple receptors for obesity, in Discovery stage.

Hypoparathyroidism Program (PTHR1):Agonist approach targeting PTHR1 for hypoparathyroidism, in Discovery stage.

Additional Programs (MultiGen™ Platform):Various programs using the MultiGen™ Platform, in Discovery stage.

Specialties

GPCR-modulating therapeutics Metabolic diseases Endocrine diseases Small molecule therapies Antibody-based therapies Neuropathic pain treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 1000000 MR: - FA: EUR 1 million FAN: 1000000	D: 2025-10-08 FD: 2025-10-08	1 investors
2	RT: Series B T: - FT: Series B	A: 60000000 MR: - FA: EUR 60M FAN: 60000000	D: 2024-07-26 FD: 2024-07-26	13 investors
3	RT: Grant T: - FT: Grant	A: 1728000 MR: - FA: 1.6 million FAN: 1728000	D: 2024-03-28 FD: 2024-03-28	1 investors

Grant Latest

2025-10-08

$1.0M

1 investor (Pro only)

Series B 2024-07-26

$60.0M

Grant 2024-03-28

$1.7M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Cedric Ververken

Chief Executive Officer

C

Christel Menet

Chief Scientific Officer

P

Paolo Vicini

Chief Development Officer

S

Stephen Dowd

Chief Business Officer

F

Frank Landolt

Chief Counsel, Intellectual Property and Legal

T

Tim Corn

Medical Advisor

View 19 more team members with Pro

Unlock Full Team Directory

Recent News